Member Info for corradus

The price was £3.16 per share on the retail offer, but as far as I know this is a separate distinct transaction. It's listed that way on HL...

TimberTrader actually posted the relevant text earlier!!

Thanks TT

Incorrect. Read the RNS...

It sounds like this may have been overlooked, which would be quite unprofessional. Anyone know other brokers the same? I would expect it to be across the board as I was told the figures are calculated externally.

Have just spoken with HL and was told it will be sorted by COB today latest. They are waiting for confirmation of the new consolidation numbers from the new provider... and unsurprisingly have been inundated with queries... of which one was mine!

No new shareholding listed yet on Hl, but the new shares are at listed (search Greatland). Current spread 300-320. Option to deal also there.

One final note on Basel 3... it's date of implementation is somewhat irrelevant - the banks will not wait. They know it is coming in the future is the relevant point. They are already buying more...

Simply put, banks will have to allocate significantly more funding to cover paper gold going forward

As stated in previous post gold has been a Tier 1 asset since Basel 1. The statement that it will become Tier 1 under Basel 3 is false.

It's the way paper gold has to be covered in Liquidity terms that is changing... and its a big change which will drive banks to want physical gold (imo).

Gold is handled differently under Basel 3, but gold remains a Tier 1 asset with 0% risk-weight under credit rules — the same as cash or reserves — this is unchanged since Basel I.

The releavant change (imo) ...

Unallocated gold (i.e., paper claims) now faces a high 85% Required Stable Funding (RSF) under the Net Stable Funding Ratio, making banks allocate significant stable funding against it — a major shift compared to prior treatment.

And to add that contrary to misconception, gold is not classified as HQLA under Basel III’s Liquidity Coverage Ratio.

Claims that gold becomes Tier 1 HQLA as of July 1, 2025 are false — no such formal change has been made.

Physical gold already enjoys Tier 1 status; no upgrade has occurred, despite online rumours... its status in this regard is unchanged.

...on final total holding, so 10, 30, 50, 70, 90....

Or odd multiples of 10 so you get half a free consolidated share :0) (rounded up)

The maximum you can lose is 9 shares. Any holding that is an odd multiple of 10 is the "best" deal.

From the scheme document:

6. FRACTIONAL ENTITLEMENTS Fractions of GRL Shares will not be issued to Scheme Shareholders and any such entitlement to a fraction of a GRL Share under this Scheme: (a) of 0.5 or more will be rounded up to the nearest whole number of GRL Shares; and (b) of less than 0.5 will be rounded down to the nearest whole number of GRL Shares, and the resulting whole numbers of GRL Shares will be issued pursuant to the Scheme.

This perhaps...

https://stockhouse.com/news/press-releases/2024/09/05/shareholders-that-lost-money-on-indivior-plc-indv-urged-to-join-class-action

Stockhouse Logo

Join Now

Sign In

Search Companies, etc

News Press Releases

Shareholders that lost money on Indivior PLC(INDV) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

INDV | 23 hours ago

NEW YORK, NY / ACCESSWIRE / September 5, 2024 / If you suffered a loss on your Indivior PLC (NASDAQ:INDV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:

https://zlk.com/pslra-1/indivior-lawsuit-submission-form?prid=100375&wire=1

or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.

THE LAWSUIT: A class action securities lawsuit was filed against Indivior PLC that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 22, 2024 and July 8, 2024.

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) the Company grossly overstated their ability to forecast the negative impact of certain legislation on the financial prospects of Indivior products, which forecasting ability was far less capable and effective than defendants had led investors and analysts to believe; (ii) defendants overstated the financial prospects of the Company's products to treat opioid use disorders and serious mental illnesses, SUBLOCADE, PERSERIS and OPVEE, and thus overstated the Company's anticipated revenue and other financial metrics; (iii) defendants knew or recklessly disregarded that because of the negative impact of certain legislation on the financial prospects of Indivior's products, Indivior was unlikely to meet its own previously issued and repeatedly reaffirmed FY 2024 net revenue guidance, including its FY 2024 net revenue guidance for SUBLOCADE, PERSERIS and OPVEE; (iv) defendants knew or recklessly disregarded that Indivior was at a significant risk of, and/or was likely to cease all sales and marketing activities related to PERSERIS; and (v) as a result of the foregoing, the Company's public statements were materially false and misleading at all relevant times.

Thanks mythyaar. Useful commentary IMO. Is there any missing from the end as it seems to finish mid-sentence?

And equally relevant is INDV agreement with Aelis Farma re AEF0117:

AEF0117, which targets disorders due to excessive cannabis use (addiction and psychosis), has shown indications of efficacy in a phase 2a clinical trial and entered a phase 2b clinical trial in the United States in Q2 2022. Aelis Farma has an exclusive option-license agreement with Indivior PLC, a leading pharmaceutical company in the treatment of addiction, for the development and commercialization of AEF0117 for disorders due to excessive cannabis use. As part of this agreement, Aelis Farma has already received $30 million (option payment). If Indivior exercises the license option at the end of the phase 2b, Aelis Farma will receive a $100 million license fee (potentially in 2024) and Indivior will take responsibility for additional development costs. The agreement also includes up to $340 million in additional payments contingent on the achievement of development, regulatory and commercial milestones, as well as royalties on net sales of AEF0117 ranging between 12% and 20%.

Analysts positive aggregate 12m price forecasts for both INDV and AELIS, both higher by 50%+. 4 and 3 analysts covering respectively, all 7 strong buy.

I share your optimism, @mythyaar. It would be disappointing if, after raising FY guidance in October and then Sublocade potential in November (before the capital markets day), the results were below expectations.

It's also encouraging that the shares in Aelis Farma, with whom Indivior have a partnership / agreement for cannabis addiction treatment (June 2021), are now trading near all time highs. Hopefully trial results will be good... All IMO.

GLA
C

https://www.webmd.com/mental-health/addiction/news/20221117/a-vaccine-against-deadly-fentanyl-might-be-near

https://www.medscape.co.uk/viewarticle/injecting-related-infection-treatment-should-include-opioid-2022a1001uug

IMV currently somewhere between 35% and 39% through the US$100m share buyback that commenced on 1 May. Total shares bought is 9,722,916, based on issued RNS data (from LSE). Average price paid to date approx 302.4p per share.
If you assume exchange rate is 0.8 US / GBP then 37% complete, so still a way to go (0.75 gives 39%, 0.85 gives 35%).